S&P 500   4,037.11 (+0.33%)
DOW   32,439.56 (+0.75%)
QQQ   302.06 (+0.04%)
AAPL   147.29 (+0.12%)
MSFT   265.27 (+1.59%)
FB   203.93 (+2.67%)
GOOGL   2,308.89 (-0.52%)
AMZN   2,248.27 (-0.57%)
TSLA   738.57 (-4.03%)
NVDA   176.53 (-0.30%)
BABA   88.10 (+0.13%)
NIO   14.94 (+4.40%)
AMD   96.47 (+1.42%)
CGC   5.82 (-1.69%)
MU   71.76 (-0.22%)
T   20.28 (+2.22%)
GE   75.33 (+0.37%)
F   13.22 (-2.07%)
DIS   106.62 (-0.66%)
AMC   11.83 (+0.17%)
PFE   51.00 (+2.16%)
PYPL   78.91 (+0.10%)
NFLX   190.24 (+1.39%)
S&P 500   4,037.11 (+0.33%)
DOW   32,439.56 (+0.75%)
QQQ   302.06 (+0.04%)
AAPL   147.29 (+0.12%)
MSFT   265.27 (+1.59%)
FB   203.93 (+2.67%)
GOOGL   2,308.89 (-0.52%)
AMZN   2,248.27 (-0.57%)
TSLA   738.57 (-4.03%)
NVDA   176.53 (-0.30%)
BABA   88.10 (+0.13%)
NIO   14.94 (+4.40%)
AMD   96.47 (+1.42%)
CGC   5.82 (-1.69%)
MU   71.76 (-0.22%)
T   20.28 (+2.22%)
GE   75.33 (+0.37%)
F   13.22 (-2.07%)
DIS   106.62 (-0.66%)
AMC   11.83 (+0.17%)
PFE   51.00 (+2.16%)
PYPL   78.91 (+0.10%)
NFLX   190.24 (+1.39%)
S&P 500   4,037.11 (+0.33%)
DOW   32,439.56 (+0.75%)
QQQ   302.06 (+0.04%)
AAPL   147.29 (+0.12%)
MSFT   265.27 (+1.59%)
FB   203.93 (+2.67%)
GOOGL   2,308.89 (-0.52%)
AMZN   2,248.27 (-0.57%)
TSLA   738.57 (-4.03%)
NVDA   176.53 (-0.30%)
BABA   88.10 (+0.13%)
NIO   14.94 (+4.40%)
AMD   96.47 (+1.42%)
CGC   5.82 (-1.69%)
MU   71.76 (-0.22%)
T   20.28 (+2.22%)
GE   75.33 (+0.37%)
F   13.22 (-2.07%)
DIS   106.62 (-0.66%)
AMC   11.83 (+0.17%)
PFE   51.00 (+2.16%)
PYPL   78.91 (+0.10%)
NFLX   190.24 (+1.39%)
S&P 500   4,037.11 (+0.33%)
DOW   32,439.56 (+0.75%)
QQQ   302.06 (+0.04%)
AAPL   147.29 (+0.12%)
MSFT   265.27 (+1.59%)
FB   203.93 (+2.67%)
GOOGL   2,308.89 (-0.52%)
AMZN   2,248.27 (-0.57%)
TSLA   738.57 (-4.03%)
NVDA   176.53 (-0.30%)
BABA   88.10 (+0.13%)
NIO   14.94 (+4.40%)
AMD   96.47 (+1.42%)
CGC   5.82 (-1.69%)
MU   71.76 (-0.22%)
T   20.28 (+2.22%)
GE   75.33 (+0.37%)
F   13.22 (-2.07%)
DIS   106.62 (-0.66%)
AMC   11.83 (+0.17%)
PFE   51.00 (+2.16%)
PYPL   78.91 (+0.10%)
NFLX   190.24 (+1.39%)
NYSE:STE

STERIS (STE) Stock Forecast, Price & News

$218.07
+1.89 (+0.87%)
(As of 05/16/2022 02:30 PM ET)
Add
Compare
Today's Range
$214.02
$218.07
50-Day Range
$212.57
$252.92
52-Week Range
$188.10
$255.93
Volume
5,968 shs
Average Volume
488,608 shs
Market Capitalization
$21.83 billion
P/E Ratio
91.24
Dividend Yield
0.80%
Beta
0.67
30 days | 90 days | 365 days | Advanced Chart
Receive STE News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

STERIS logo

About STERIS

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company was founded in 1985 and is based in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
85915210
Employees
13,000
Year Founded
1987

Sales & Book Value

Annual Sales
$4.59 billion
Cash Flow
$8.86 per share
Book Value
$45.59 per share

Profitability

Net Income
$397.40 million
Pretax Margin
8.92%

Debt

Price-To-Earnings

Miscellaneous

Free Float
98,986,000
Market Cap
$21.83 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Ex-Dividend for 3/24 Dividend
2/24/2022
Dividend Payable
3/24/2022
Today
5/16/2022
Ex-Dividend for 6/28 Dividend
6/13/2022
Dividend Payable
6/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
3/31/2023

Social Links


MarketRank

Overall MarketRank

2.72 out of 5 stars

Medical Sector

50th out of 1,403 stocks

Surgical Appliances & Supplies Industry

2nd out of 28 stocks

Analyst Opinion: 2.5Community Rank: 4.0Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













STERIS (NYSE:STE) Frequently Asked Questions

Is STERIS a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS
or view top-rated stocks.

Are investors shorting STERIS?

STERIS saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 950,900 shares, a drop of 23.9% from the April 15th total of 1,250,000 shares. Based on an average daily volume of 486,300 shares, the short-interest ratio is currently 2.0 days.
View STERIS's Short Interest
.

When is STERIS's next earnings date?

STERIS is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for STERIS
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) issued its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported $1.99 EPS for the quarter, beating the consensus estimate of $1.82 by $0.17. The medical equipment provider earned $1.20 billion during the quarter, compared to the consensus estimate of $1.16 billion. STERIS had a net margin of 5.32% and a trailing twelve-month return on equity of 11.83%. During the same quarter in the previous year, the firm earned $1.48 EPS.
View STERIS's earnings history
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS announced a quarterly dividend on Wednesday, May 4th. Stockholders of record on Tuesday, June 14th will be paid a dividend of $0.43 per share on Tuesday, June 28th. This represents a $1.72 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Monday, June 13th.
View STERIS's dividend history
.

Is STERIS a good dividend stock?

STERIS pays an annual dividend of $1.72 per share and currently has a dividend yield of 0.80%. STERIS has been increasing its dividend for 17 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of STERIS is 71.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 17.50% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY 2023 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $8.55-$8.75 for the period, compared to the consensus EPS estimate of $8.19. The company issued revenue guidance of -.

What price target have analysts set for STE?

6 Wall Street analysts have issued 1-year target prices for STERIS's shares. Their forecasts range from $250.00 to $275.00. On average, they anticipate STERIS's share price to reach $264.00 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for STERIS
or view top-rated stocks among Wall Street analysts.

Who are STERIS's key executives?
STERIS's management team includes the following people:
What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

What is STERIS's stock symbol?

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Who are STERIS's major shareholders?

STERIS's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.51%), BlackRock Inc. (8.18%), WCM Investment Management LLC (6.46%), Massachusetts Financial Services Co. MA (4.36%), State Street Corp (4.22%) and APG Asset Management N.V. (3.43%). Company insiders that own STERIS stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS
.

Which institutional investors are selling STERIS stock?

STE stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, WCM Investment Management LLC, Mackenzie Financial Corp, UBS Group AG, Bank of Nova Scotia, RMB Capital Management LLC, Strs Ohio, and Federated Hermes Inc.. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Michael J Tokich, and Renato Tamaro.
View insider buying and selling activity for STERIS
or view top insider-selling stocks.

Which institutional investors are buying STERIS stock?

STE stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Great West Life Assurance Co. Can, Sumitomo Mitsui Trust Holdings Inc., JPMorgan Chase & Co., Assenagon Asset Management S.A., Vanguard Group Inc., Jennison Associates LLC, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for STERIS
or or view top insider-buying stocks.

How do I buy shares of STERIS?

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STERIS's stock price today?

One share of STE stock can currently be purchased for approximately $218.07.

How much money does STERIS make?

STERIS has a market capitalization of $21.83 billion and generates $4.59 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $2.389990 on an earnings per share basis.

How many employees does STERIS have?

STERIS employs 13,000 workers across the globe.

When was STERIS founded?

STERIS was founded in 1987.

What is STERIS's official website?

The official website for STERIS is www.steris.com.

How can I contact STERIS?

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000, via email at [email protected], or via fax at 440-639-4457.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.